Exelixis (EXEL) Projected to Post Earnings on Tuesday

Exelixis (NASDAQ:EXEL) is expected to release its earnings data before the market opens on Tuesday, February 4th. Analysts expect Exelixis to post earnings of $0.39 per share and revenue of $563,490.00 billion for the quarter.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same period in the previous year, the company posted $0.10 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. On average, analysts expect Exelixis to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Exelixis Trading Up 1.0 %

Shares of NASDAQ EXEL opened at $32.72 on Tuesday. The stock has a 50 day moving average of $34.84 and a 200-day moving average of $29.89. The company has a market capitalization of $9.34 billion, a P/E ratio of 20.97, a P/E/G ratio of 0.72 and a beta of 0.53. Exelixis has a 12 month low of $20.01 and a 12 month high of $37.59.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on EXEL. Royal Bank of Canada restated an “outperform” rating and issued a $34.00 price target on shares of Exelixis in a research note on Wednesday, October 30th. Truist Financial boosted their price target on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research note on Monday. Stifel Nicolaus boosted their price target on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, October 16th. Stephens reiterated an “equal weight” rating and set a $29.00 target price on shares of Exelixis in a research report on Monday. Finally, Piper Sandler upped their target price on Exelixis from $36.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $35.81.

Insider Buying and Selling at Exelixis

In related news, EVP Patrick J. Haley sold 41,588 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $34.36, for a total transaction of $1,428,963.68. Following the sale, the executive vice president now owns 288,665 shares in the company, valued at $9,918,529.40. This represents a 12.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the sale, the executive vice president now owns 486,059 shares in the company, valued at approximately $17,823,783.53. The trade was a 10.99 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 289,736 shares of company stock worth $10,139,360. Insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.